Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which
Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which havebeen designed with input from U.S. clinicians, according to RaviSharma, vice president of marketing.
At the top of Toshiba's list of product introductions is Flexart,a new 0.5-tesla MRI scanner to be shown as a works-in-progress.Flexart uses a helium-only superconducting magnet designed forlow cryogen boil-off and low maintenance. The system is activelyshielded to reduce eddy currents and can be sited in a space assmall as 45 square meters, Sharma said.
"This has been developed mainly for community hospitalsand hospitals that are going to see high growth in the managed-careenvironment," he said.
Flexart will be priced at about $1 million and will be positionedas Toshiba's premium mid-field offering. The company will continueto sell MRT-50A, its existing mid-field product.
In CT, Toshiba will unveil Xpress/SX, an upgrade to the vendor'sXpress slip-ring CT scanner. The upgrade will add solid-statedetectors to Xpress, which enable faster helical scanning andimproved image quality, Sharma said.
The system is powered by a 48-kW generator with an output of400 mAs and runs a 3.5-million heat unit x-ray tube. Xpress/SXhas Food and Drug Administration marketing clearance. It willbe priced at about $1 million, Sharma said.
Other new product introductions include:
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.